Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-07
2011-06-07
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S123100
Reexamination Certificate
active
07956046
ABSTRACT:
Oligosaccharide mixtures comprising anti-Xa activities of from 190 IU/mg to 450 IU/mg and anti-IIa activities of less than 0.2 IU/mg; and having constituent oligosaccharides with an average molecular weight of from 1800 to 2400 Daltons, constituent oligosaccharides comprise from 2 to 16 saccharide units, a 4,5-unsaturated uronic acid 2-O-sulfate unit at one end, and comprising at least one ΔIIa-IIs-Is hexasaccharide sequence are described. Processes for preparing the oligosaccharide mixtures, pharmaceutical compositions and articles of manufacture comprising the oligosaccharide mixtures are described. Methods of treatment and prevention comprising administering the oligosaccharide mixtures are described.
REFERENCES:
patent: 4168377 (1979-09-01), Choay et al.
patent: 4401662 (1983-08-01), Lormeau et al.
patent: 4401758 (1983-08-01), Lormeau et al.
patent: 4440926 (1984-04-01), Mardiguian
patent: 4474770 (1984-10-01), Lormeau et al.
patent: 4500519 (1985-02-01), Lormeau et al.
patent: 4533549 (1985-08-01), Lasker
patent: 4686288 (1987-08-01), Lormeau et al.
patent: 4826827 (1989-05-01), Lormeau et al.
patent: 4981955 (1991-01-01), Lopez
patent: 4987222 (1991-01-01), DeAmbrosi et al.
patent: 5380716 (1995-01-01), Conrad et al.
patent: 5389618 (1995-02-01), Debrie
patent: 5576304 (1996-11-01), Kakkar et al.
patent: RE35770 (1998-04-01), Lormeau et al.
patent: 6001820 (1999-12-01), Hirsh et al.
patent: 6075013 (2000-06-01), Weitz et al.
patent: 6103705 (2000-08-01), Uzan et al.
patent: 6197943 (2001-03-01), Casu et al.
patent: 6384021 (2002-05-01), Mardiguian
patent: 6617316 (2003-09-01), Mourier et al.
patent: RE38743 (2005-06-01), Debrie
patent: 6969705 (2005-11-01), Pecquet et al.
patent: 2002/0055621 (2002-05-01), Diaz et al.
patent: 2004/0171819 (2004-09-01), Viskov
patent: 2005/0171055 (2005-08-01), Pecquet et al.
patent: 2008/0182820 (2008-07-01), Viskov
patent: B-70519/81 (1981-11-01), None
patent: 0 027 089 (1981-04-01), None
patent: 0 037 319 (1981-10-01), None
patent: 0 040 144 (1981-11-01), None
patent: 0 114 589 (1984-08-01), None
patent: 0 293 539 (1988-12-01), None
patent: 1 070 503 (2001-01-01), None
patent: 2 077 533 (1995-11-01), None
patent: 2 663 639 (1991-12-01), None
patent: 2811992 (2002-01-01), None
patent: WO 81 02737 (1981-10-01), None
patent: WO 98/55515 (1998-12-01), None
patent: WO 0129055 (2001-04-01), None
patent: WO 02/08295 (2002-01-01), None
Galezowski, W. et al., “Homoconjugated Hydrogen Bonds with Amidine and Guanidine Bases, Osmometric, Potentiometric and FTIR Studies,” J. Chem. Soc., Faraday Transactions, 93(15), pp. 2515-2518, 1997.
International Search Report mailed Dec. 6, 2001, for PCT Application No. PCT/FR01/02332, filed Jul. 18, 2001 (4 pages).
Schwesinger, R. et al., “Peralkylated Polyaminophosphazenes—Extremely Strong, Neutral Nitrogen Bases,” Angew. Chem. Int. Ed. Engl., 26(11), pp. 1167-1169, 1987.
Schwesinger, R., et al., “How Strong and How Hindered Can Uncharged Phosphazene Bases Be?” Angew. Chem. Int. Ed. Engl., 32, No. 9, pp. 1361-1363, 1993.
Ungria, Javier, European Patent Office letter, Re: European Patent Application No. 01955436.9 (Publication No. EP-1307491) in the name of Aventis Pharma, S.A., pp. 1-4, Jul. 30, 2004.
Vila, P. et al., “Preparation of Saccharide Oligomers by Chemical Depolymerization of Heparin Derivatives,” Chemical Abstracts Service, Database Accession No. 125:303695 w, pp. 163-164, Dec. 9, 1996.
Office Action dated May 5, 2008, in U.S. Appl. No. 11/096,146.
English language Derwent abstract of EP 0 040 144 A1, Nov. 18, 1981.
English language Derwent abstract of EP 0 037 319 A1, Oct. 7, 1981.
English language Derwent abstract of FR 2 663 639 A1, Dec. 27, 1991.
English language Derwent abstract of EP 0 027 089 A1, Apr. 15, 1981.
English language Derwent abstract of ES 2 077 533 A1, Nov. 16, 1995.
English language Derwent abstract of WO 81 02737 A1, Oct. 1, 1981.
English language Derwent abstract of EP 0 293 539 A2, Dec. 7, 1988.
Barrowcliffe et al., “Anticoagulant Activities of Lung and Mucous Heparins,” Thromb. Res., 12(1): 27-36 (1977).
Barrowcliffe et al., “Standardization of Low Molecular Weight Heparins: A Collaborative Study,” Thrombosis and Haemostasis, 54(3): 675-679 (1985).
Barrowcliffe et al., “An International Standard for Low Molecular Weight Heparin,” Thrombosis and Haemostasis, 60(1): 1-7 (1988).
Choay et al., “Structural Studies on a Biologically Active Hexasaccharide Obtained from Heparin,” Annals of the New York Academy of Sciences, 370: 644-649 (1981).
Hook et al., “Anticoagulant Activity of Heparin: Separation of High-Activity and Low-Activity Heparin Species by Affinity Chromatography on Immobilized Antithrombin,” F.E.B.S. Letters, 66(1): 90-93 (1976).
Lane et al., “Anticoagulant Activities of Four Unfractionated and Fractionated Heparins,” Thromb. Res., 12(2): 257-271 (1978).
Teien et al., “Evaluation of a Amidolytic Heparin Assay Method: Increased Sensitivity by Adding Purified Antithrombin III,” Thromb. Res., 10(3): 399-410 (1977).
Andersson et al., “Molecular Weight Dependency of the Heparin Potentiated Inhibition of Thrombin and Activated Factor X, Effect of Heparin Neutralization in Plasma,” Thromb. Res., 15(3/4): 531-541 (1979).
Declaration Pursuant to 37 C.F.R. § 1.132 of Dr. Christian Viskov, dated Nov. 26, 2003, for U.S. Appl. No. 10/430,435, filed May 7, 2003, including attached Tables 1(a), 1(b), and 2 (8 pages total).
Office Action dated Jul. 30, 2002 in U.S. Appl. No. 09/090,797.
Office Action dated Mar. 11, 2003 in U.S. Appl. No. 09/909,797.
Office Action dated Jul. 14, 2003 in U.S. Appl. No. 09/909,797.
Office Action dated May 17, 2004 in U.S. Appl. No. 09/909,797.
Office Action dated Jan. 21, 2005 in U.S. Appl. No. 09/909,797.
Office Action dated Aug. 9, 2006 in U.S. Appl. No. 10/680,934.
Office Action dated Apr. 19, 2006 in U.S. Appl. No. 10/680,934.
Office Action dated Mar. 31, 2006 in U.S. Appl. No. 11/096,146.
Office Action dated Nov. 22, 2006 in U.S. Appl. No. 11/096,146.
Office Action dated Aug. 6, 2007 in U.S. Appl. No. 11/096,146.
Laux Volker
Mourier Pierre
Viskov Christian
Aventis Pharma S.A.
Jiang Shaojia Anna
McCarter & English LLP
White Everett
LandOfFree
Oligosaccharide mixtures derived from heparin, preparation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligosaccharide mixtures derived from heparin, preparation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligosaccharide mixtures derived from heparin, preparation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2689955